The distal hereditary motor neuropathy (distal HMN) or the spinal form of Charcot-Marie-Tooth (CMT) disease is an exclusively motor disorder of the peripheral nervous system. The disorder clinically resembles the hereditary motor and sensory neuropathies (HMSN) type I and type II or CMT type 1 and type 2. Distal HMN might also be related to the spinal muscular atrophies (SMA) since, in both disorders, the lower motor neurons are affected. Electrophysiological and neuropathological examinations of peripheral nerves show the absence of sensory involvement. We performed a genome search in an extended Belgian family with autosomal dominant distal HMN type II. Significant linkage was obtained with markers located at chromosome 12q24, and the gene for distal HMN II was assigned to the 13 cM interval between D12S86 and D12S340.
INTRODUCTION
Charcot-Marie-Tooth (CMT) disease is a common inherited disorder of the peripheral nervous system characterized by weakness and atrophy of distal limb muscles, diminished or absent deep tendon reflexes and often pes cavus deformity. In some patients, sensory disturbances in the distal parts of the limbs can be detected on clinical examination, but these signs are seldom prominent. Clinical, electrophysiological and neuropathological examinations have shown that CMT is a heterogeneous disorder that can be subdivided into several subtypes: CMT type 1 (CMT1), CMT type 2 (CMT2) and the spinal form of CMT (spinal CMT). CMT1 is a demyelinating polyneuropathy with severely slowed motor and sensory nerve conduction velocities (NCV) and signs of de-and remyelination with onion-bulb formation on peripheral nerve biopsies. CMT2 shows mainly axonal pathology, the motor and sensory NCVs are slightly reduced and the amplitudes of the sensory responses are diminished (1) . The spinal form of CMT is an exclusively motor neuropathy since the axons of lower motor neurons are affected.
On clinical examination, spinal CMT can hardly be distinguished from CMT1 and CMT2 because unequivocal sensory signs are often absent in these disorders. Absence of sensory involvement can only be proven by normal sensory NCVs and a normal sensory nerve biopsy (2, 3) .
In the more descriptive classification of Dyck et al. (1) , CMT1 and CMT2 are classified as hereditary motor and sensory neuropathies (HMSN) type I and II, respectively. The spinal muscular atrophy of CMT type is included in the distal hereditary motor neuropathy (distal HMN) group. Distal HMN is genetically heterogeneous, and both autosomal dominant and autosomal recessive modes of inheritance have been described. A nosology of distal HMN with a subdivision in seven types based on inheritance pattern and age at onset has been proposed (3).
Molecular genetic studies have identified the underlying gene defects in several CMT subtypes. The majority of CMT1 patients (CMT1A), i.e. 71%, have a 1.5 Mb duplication in chromosome 17p11.2 (4-6), containing the peripheral myelin protein 22 (PMP22) gene. A minority of dominantly inherited CMT1 patients harbour point mutations in the PMP22 gene or in the major peripheral myelin protein zero (MPZ) gene on chromosome 1q22-q23 (CMT1B). Mutations in the gap junction protein connexin-32 (Cx32) gene are responsible for the X-linked variant of CMT (7) . Disease loci for CMT2 were located on chromosome 1p35-p36 (CMT2A) and recently on chromosome 3q13-q22 (CMT2B) (8, 9) . One form of the autosomal recessive CMT type (CMT4A) was mapped on chromosome 8q13-q21 (10). Christodoulou et al. (11) assigned the distal HMN type V to chromosome 7p.
RESULTS
We previously performed a clinical and genetic study of a six generation family with autosomal dominant inheritance of distal HMN II (or spinal CMT) neuropathy. The clinical, electrophysiological and histopathological features of some of the patients have been described in detail elsewhere (12) . Updated neurological examinations were obtained in the at-risk generation and we were able to diagnose three more patients, i.e. individuals VI-6, VI-10 and VI-13 ( Fig. 1) . Also, a new branch of the *To whom correspondence should be addressed (12) . For each marker, the alleles were numbered from the largest to the smallest allele as they appeared in the pedigree. The black bars represent the disease haplotype linked to distal HMN II. Symbols: circles = females, squares = males, slashed symbols = deceased persons.
pedigree (offspring of III-12) was sampled and included in this study. Linkage was previously excluded at the CMT1 loci on chromosomes 17p11.2-12 (CMT1A) and 1q22-23 (CMT1B), and at the proximal spinal muscular atrophy (SMA) locus on 5q11.2-13.3, respectively (12) .
A genome-wide search was initiated using the hybridization-based technology provided by the Human Genome Center Généthon (Evry, France). A total of 187 (CA) n repeat polymorphisms located on chromosomes 1-12 were typed at a mean distance of 15 cM (13). One hundred and thirty five (CA) n repeats, i.e. 72%, could be interpreted and were analysed for linkage by calculating two-point LOD scores (Z) at different recombination fractions (θ). This analysis indicated that 90.3% of chromosomes 1-12 could be excluded for linkage to distal HMN II, comprising the CMT2 loci on 1p35-36 (CMT2A) and 3q13-22 (CMT2B) (8, 9) , the autosomal recessive CMT locus on 8q13-21 (CMT4A) (10) and the distal HMN type V on 7p (11). Significant linkage (Z = 3.66, θ = 0.05) was obtained with D12S86, suggesting the presence of the distal HMN II locus on chromosome 12q (Table 1) . Positive LOD scores were also obtained with the markers D12S78 (Z = 2.19, θ = 0.19) and D12S367 (Z = 0.45, θ = 0.33) included in the genome-wide search and located respectively proximal and distal to D12S86 (Fig. 2) .
In order to refine the location of the distal HMN type II gene, an additional five (CA) n dinucleotide repeat markers were analysed ( Fig. 2) : D12S79, D12S342, D12S340, D12S324 and D12S386 (13, 14) . All markers gave positive LOD scores (Table 1) . Conclusive LOD scores in the absence of recombinants were obtained with D12S342 (Z = 3.10 at θ = 0.00). Segregation of all markers was examined in the pedigree (Fig. 1) . With D12S86, an interbranch recombinant must have occurred since the affected offspring of III-6 and III-12 are segregating a different allele as compared with patient IV-17. With D12S340, an obligate recombinant is observed in patient IV-15 and in the unaffected individual VI-5. The latter individual is currently 26 years old. The mean onset age in the family is 20.9 ± 6.2 years. Based on the informative recombinants, we can define the candidate region for the distal HMN II gene as the region comprised between the markers D12S86 and D12S340, a region of 13 cM on the sex average genetic map (Fig. 2) . This area corresponds to ∼ 5 Mb based on the published physical mapping data using yeast artificial chromosomes (YACs) (15). Several genes, active in the peripheral nervous system, might be located in the distal HMN II candidate region. One of them is the phospholipase A2 (PLA2A) gene located within 12q23-24.1 (16) . PLA2A catalyses the release of fatty acids from glycero-3-phosphocholines and has been isolated from several tissues, including the brain. It was suggested that PLA2A has an important function in the protection of membranes from oxidative injury (17) . PLA2A activity might also be significant in demyelination of Schwann cells (18) . We examined linkage of PLA2A to distal HMN II using a (AAT) n trinucleotide repeat located in the first intron (19, 20) . A two-point LOD score of 6.69 is obtained in the absence of recombinants. Intermarker LOD scores calculated for PLA2A with D12S86 (Z = 6.39, θ = 0.02), D12S342 (Z = 4.2, θ = 0.07) and D12S340 (Z = 5.54, θ = 0.03) indicated that PLA2A could be located within the distal HMN II candidate region. Segregation analysis showed that a location of PLA2A fits within the distal HMN II candidate region (Fig. 1) . Based on our results, we cannot exclude PLA2A as the distal HMN II gene.
DISCUSSION
The distal HMN account for 10% of all cases with CMT neuropathy, the most common hereditary disorder of the peripheral nervous system (21) . Seven distal HMN subtypes have been identified (3) . So far, only a locus for distal HMN V was assigned to chromosome 7p in a single Bulgarian pedigree (11) . We have identified a locus for distal HMN II on chromosome 12 within the 13 cM interval between D12S86 and D12S340 in a single Belgian family. This is the first locus for distal HMN II. Linkage studies with chromosome 12q markers in other families with distal HMN II need to be performed in order to analyse the presence of genetic heterogeneity. Also, genetic analysis of other chromosome 12q-linked distal HMN II pedigrees may help to narrow down the candidate region based on informative recombinants.
Genetic linkage analysis using an intronic PLA2A polymorphic marker provided evidence that PLA2A is located within the candidate region. According to Paul and Gregson (18) , PLA2A may have a role in demyelination in neuronal tissues. Anti-PLA2 antisera indicated that the enzyme concentration increases in Schwann cells during Wallerian degeneration in peripheral nerve. Sequence analysis of the entire coding region of PLA2A (20) is currently being performed to see whether disease specific mutations can be found.
Besides PLA2A, other candidate genes have been mapped in the same chromosomal region including the neuronal nitric oxide synthase (NOS) gene and the human achaete-scute homologue 1 (HASH1) gene (22, 23) . Neuronal NOS is expressed in spinal motor neurons and in dorsal root ganglia (24, 25) and is responsible for the production of nitric oxide, a neurotransmitter which plays a role in the morphogenesis of the nervous system and synaptic plasticity (25, 26) . HASH1 is expressed in the developing central and peripheral nervous system, and in neuroendocrine tumours in which it might act as a regulator of cellular differentiation (23, 27, 28) . The exact locations of NOS and HASH1 relative to the distal HMN II candidate region remain to be determined.
MATERIALS AND METHODS

Family data
In 1992 we performed a genealogical study of the Belgian distal HMN II family comprising 86 persons over six generations and showing autosomal dominant inheritance of the disease (12) . Figure 1 shows the linkage pedigree of the affected individuals and escapees. Information on deceased family members and patients who were not available for clinical examination was gathered from close relatives. Persons were scored as being affected when at least some weakness of the extensor muscles of the toes and feet was detected on routine neurological examination. Some individuals have not reached the age of onset and therefore their status remains uncertain. Most patients in the Belgian distal HMN II family remembered that their disease started at an age between 15 and 25 years. Occasionally, older patients mentioned a later onset age of the disease. Follow-up examination of the youngest generation confirmed the earlier onset between 15 and 25 years of age. Normal motor and sensory nerve conduction velocities were observed in 10 clinically affected patients. In three of them, standard concentric needle electromyography showed chronic neurogenic alterations.
DNA analysis
The methods used for the genome search are described in detail by Vignal et al. (29) . In our laboratory, we hybridized the (CA) n repeat amplification products, which were transferred to nylon membranes, with [γ-32 P]dATP (Amersham, UK) end-labelled oligonucleotide primers using T4 polynucleotide DNA kinase (Bethesda Research Laboratories, UK). The membranes were exposed for autoradiography to Kodak Ortho-G films (Kodak, Japan). Fine mapping was performed with D12S79 (AFM067yc5), D12S340 (AFM294zg1), D12S324 (AFM234tb10), D12S386 (Mfd53) and PLA2A, using [γ-32 P]dATP end-labelled oligonucleotide primers in PCR reactions. The PCR products were separated by standard electrophoresis on 6% polyacrylamide-8 M ureum gels, vacuum dried and autoradiographed. D12S342 (AFM294ze9) was fluorescently labelled and analysed with the 373A automated DNA sequencer provided with the GENESCAN software according to the manufacturer's conditions (Applied Biosystems Incorporation, Foster City, USA).
Linkage analysis
The standard likelihood method was used to compute two-and multi-point LOD scores (Z) at a given recombination distance (θ) with the FASTLINK computer package version 2.1 (30, 31) . Distal HMN type II was assessed in the linkage as an autosomal dominant trait, with a gene frequency of 0.0001 and equal male and female recombination values. LOD scores were calculated including both affected and unaffected individuals. To the asymptomatic at-risk individuals a probability of being a gene carrier was assigned at their age of clinical and electrophysiological examination. Six age-dependent penetrance classes were obtained from family data according to the age at onset curve (32) . A disease penetrance of 99% is reached at 41 years. For the genome-wide search, equal allele frequencies were assumed and the genetic distances between the loci were obtained from Gyapay et al. (13) . Exclusion limits were calculated with Haldanes' mapping function, from θ at Z = -2 (33). The chromosome 12q linkage was computed with allele frequencies estimated from all typed individuals in the family using the program DOWNFREQ version 1.1 (34) .
